Wren Laboratories utilizes liquid biopsy mRNA technology and machine learning to provide precise, non-invasive cancer diagnostics tailored to individual molecular profiles. Their assays, including NETest for neuroendocrine tumors and PROSTest for prostate cancer, enable early detection, monitoring of minimal residual disease, and personalized treatment planning, improving patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer diagnostics often rely on invasive biopsies, which can be risky, painful, and may not fully represent the tumor's molecular profile. Monitoring treatment response and detecting minimal residual disease also present challenges, often requiring repeated invasive procedures.
Solution
Wren Laboratories offers non-invasive cancer diagnostics using liquid biopsy mRNA technology and machine learning to provide personalized insights into a patient's unique molecular profile. Their assays, such as NETest for neuroendocrine tumors and PROSTest for prostate cancer, enable early cancer detection, monitoring of minimal residual disease, and personalized treatment planning. By analyzing mRNA expression patterns in blood samples, Wren Laboratories provides clinicians with real-time information to guide treatment decisions and improve patient outcomes. The company's multi-gene mRNA expression technology offers a comprehensive and dynamic view of cancer biology, facilitating more informed and effective cancer management.
Target Audience
The primary target audience includes oncologists, pathologists, and pharmaceutical companies involved in cancer research and drug development.
Features
- Liquid biopsy mRNA technology for non-invasive cancer diagnostics
- Machine learning algorithms for personalized molecular profiling
- NETest assay for neuroendocrine tumor detection and monitoring
- PROSTest assay for prostate cancer detection and monitoring
- Assays in development for colorectal, lung, and breast cancers
- Monitoring of minimal residual disease
- Support for drug development from discovery to companion diagnostic development
- CLIA, CAP, and NYSDOH-licensed laboratory